SLC7A11 and prostate carcinoma: Lin et al. reported that SLC7A11 is widely expressed in multiple human cancers, and its up-regulation is correlated with poor survival outcomes in patients with breast cancer, prostate cancer, and papillary thyroid carcinoma (9).